$TXMD News
Last published 3mo ago
- 3mo agoTXMDTherapeuticsMD Announces Second Quarter 2026 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30,
- 6mo agoTXMDTherapeuticsMD Announces First Quarter 2026 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter
- 7mo agoTXMDTherapeuticsMD Announces Full Year 2025 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year
- 12mo agoTXMDTherapeuticsMD Announces Third Quarter 2025 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third
- 1y agoTXMDTherapeuticsMD Announces Second Quarter 2025 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter
- 1y agoTXMDTherapeuticsMD Announces Full Year 2024 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024
- 1y agoTXMDTherapeuticsMD Announces Third Quarter 2024 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third
- 2y agoTXMDTherapeuticsMD Announces Second Quarter 2024 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second
- 2y agoTXMDTherapeuticsMD Announces First Quarter 2024 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First
- 2y agoTXMDTherapeuticsMD Announces Full Year 2023 Financial ResultsBusiness Wire• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the
- 2y agoTXMDTherapeuticsMD Announces Third Quarter 2023 Financial ResultsBusiness WireFocus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company
- 3y agoTXMDTherapeuticsMD Announces Second Quarter 2023 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2023. "The
- 3y agoTXMDTherapeuticsMD Announces First Quarter 2023 Financial ResultsBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2023. First
- 3y agoTXMDTherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionBusiness WireTherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ:TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2022. "As a result
- 3y agoTXMDTherapeuticsMD Completes Transaction to License Its Products to Mayne PharmaBusiness Wire- Mayne Pharma gains exclusive U.S. commercialization rights for TXMD's products and acquires certain assets - - TXMD received approximately $153.1 million at closing; portion of proceeds used to repay all outstanding
- 3y agoTXMDTherapeuticsMD Announces Definitive Agreements to License its Products to Mayne PharmaBusiness Wire- TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minimum royalty payments, and up
- 4y agoTXMDTherapeuticsMD Announces Additional $7 Million Private PlacementBusiness WireMaturity Date of Financing Agreement Extended to November 30, 2022 TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today that it
- 4y agoTXMDTherapeuticsMD Announces $7 Million Private PlacementBusiness WireMaturity Date of Financing Agreement Extended to October 31, 2022, with the Ability to Extend to November 30, 2022, if Additional Capital is Raised TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women'
- 4y agoTXMDTherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive OfficersBusiness Wire- Robust Strategic Alternatives Process Continues - TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TherapeuticsMD" or the "Company") an innovative, leading women's healthcare company, announced today the appointment of Dr. Brian Bernick and Mr. Mark Glickman
- 4y agoTXMDTherapeuticsMD Announces Second Quarter 2022 Financial ResultsBusiness Wire- Quarterly total net revenue of $28.6 million - - ANNOVERA® TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, lead
- 4y agoTXMDTherapeuticsMD, Inc. (TXMD) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsTXMD earnings call for the period ending June 30, 2022.
- 4y agoCVMHSTOTXMDATISCEL-SCI Appoints Dr. Gail Naughton to Its Board of DirectorsBusiness WirePioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naugh
- 4y agoTXMDTherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022Business Wire-Executive Management to Host Conference Call on August 15, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its second quarter
- 4y agoTXMDTherapeuticsMD Secures $15 Million Equity Investment from Rubric CapitalBusiness WireCompany Also Reaches Agreement with Sixth Street Partners to Extend the Maturity Date of its Financing Agreement to September 30, 2022 with the Ability to Extend to November 30, 2022 if Additional Capital is Received TherapeuticsMD, Inc. (NASDAQ:TXMD
- 4y agoTXMDTherapeuticsMD Announces Expiration of Tender OfferBusiness WireCompany anticipates termination of Merger Agreement with EW Healthcare Partners TherapeuticsMD, Inc. (NASDAQ:TXMD), ("TXMD" or the "Company") an innovative, leading women's healthcare company, announced today that Athene Merger, Inc., an affiliate of
- 4y agoTXMDEW Healthcare Partners Announces Extension of TherapeuticsMD Tender OfferPR NewswireTherapeuticsMD has previously stated that absent the successful closing of this transaction, the Company would likely be required to file for protection under Chapter 11. BOCA RATON, Fla., July 6, 2022 /PRNewswire/ -- EW Healthcare Partners ("EW"),
- 4y agoTXMDEW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMDPR NewswireNEW YORK, June 6, 2022 /PRNewswire/ -- EW Healthcare Partners (together with its consolidated subsidiaries and affiliates "EW") announced today that its affiliate, Athene Merger Sub, Inc. ("Purchaser"), commenced the previously announced cash tender off
- 4y agoTXMDTherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMDBusiness WireTherapeuticsMD, Inc. (NASDAQ:TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it has entered into a definitive merger agreement to be acquired by an affiliate of EW Healthcare Par
- 4y agoTXMDTherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®Business Wire- ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth control - - With this approval, the Company expects a significant reduction in its manufacturing batch rejections and an increase in future product supply and will ena
- 4y agoTXMDTherapeuticsMD Announces First Quarter 2022 Financial ResultsBusiness Wire- Quarterly total net product revenue of $19.3 million -- ANNOVERA® TRx of 8,014, an increase of 27% over Q1 2021 -- Announced and completed vitaCare divestiture in five weeks -- Conference call scheduled for 4:30 p.m. ET today - TherapeuticsMD,
- 4y agoTXMDTherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsTXMD earnings call for the period ending March 31, 2022.
- 4y agoTXMDTherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022Business Wire-Executive Management to Host Conference Call on May 16, 2022, at 4:30 p.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its first quarter 202
- 4y agoGDRXTXMDTherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 MillionBusiness WireTherapeuticsMD, Inc. (NASDAQ:TXMD), ("TXMD" or the "Company") an innovative, leading women's healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ:GDRX), in a cash transaction valued at $1
- 4y agoTXMDTherapeuticsMD Announces Fourth Quarter 2021 Financial ResultsBusiness Wire- Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women's healthcare -- Amended credit terms with Sixth Street in support of a new capitalization plan -- Conference call sc
- 4y agoTXMDTherapeuticsMD, Inc. (TXMD) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsTXMD earnings call for the period ending December 31, 2021.
- 4y agoCNRINDOTXMDUSWS+1Thinking about buying stock in Indonesia Energy, TherapeuticsMD, Cornerstone Building Brands, Vermilion Energy, or US Well Services?PR NewswireNEW YORK, March 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, TXMD, CNR, VET, and USWS. T
- 4y agoGDRXTXMDTherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRxBusiness WireGoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare's financial performance through 2023 TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, lea
- 4y agoTXMDTherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022Business Wire-Executive Management to Host Conference Call on March 10, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. ("TXMD" or the "Company") (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced that it will report its fourth quarter
- 4y agoIRTCTXMDKaren L. Ling joins Galderma's Advisory CommitteeBusiness WireGalderma, the world's largest independent dermatology company, announced today that Karen L. Ling will join its Advisory Committee, effective March 1, 2022. Karen Ling has a tremendous track record in executive roles at AIG, Allergan, Merck and Wyeth
- 4y agoCCJLODENKLANMTR+1Thinking about buying stock in 9 Meters Biopharma, TherapeuticsMD, Cameco Corp, Nikola Corp, or Comstock Mining?PR NewswireNEW YORK, Jan. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NMTR, TXMD, CCJ, NKLA, and LODE. To
- 4y agoGNPXNCLHSNGXTXMD+1Thinking about buying stock in Genprex, TherapeuticsMD, Soligenix, Norwegian Cruise Line, or Zomedica?PR NewswireNEW YORK, Jan. 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNPX, TXMD, SNGX, NCLH, and ZOM. T
- 4y agoTXMDApproval of Bijuva, Nda #210132 (Efficacy)FDA Approved DrugsApproval Date: 12/28/2021; Drug Name: Bijuva, Nda #210132; Active Ingredients: ESTRADIOL; PROGESTERONE; Company: Therapeuticsmd Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 210132
- 4y agoTXMDU.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®Business Wire- FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application (sNDA) -- FDA provided recommendations and requested additional information to address the issues
- 4y agoTXMDTherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry DateBusiness WireTherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amn
- 5y agoTXMDTherapeuticsMD Announces Third Quarter 2021 Financial ResultsBusiness Wire- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 - - Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savi
- 5y agoTXMDTherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive OfficerBusiness Wire- Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ:TXMD) (TXMD or the Company), an innovative, leading women's healthcare company, to
- 5y agoTXMDTherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsTXMD earnings call for the period ending September 30, 2021.
- 5y agoTXMDTherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021Business Wire-Executive Management to Host Conference Call on November 11, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ:TXMD) ("TXMD" or the "Company"), an innovative, leading women's healthcare company, today announced that it will report its third quarter
- 5y agoTXMDTherapeuticsMD Announces Appointment of Mark Glickman as Chief Business OfficerBusiness WireTherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women's healthcare company, today announced the appointment of Mark Glickman as the Company's Chief Business Officer. Mr. Glickman previously served as Chief Commercial Officer of Esperion an
- 5y agoTXMDTherapeutics MD Is Urging Women to 'Take Pause' During Menopause Awareness MonthBusiness WireSeptember is Menopause Awareness month, and TherapeuticsMD aims to de-stigmatize and provide education every woman should know about menopause In the next ten years, there will be more than 1.2 billion women worldwide in menopausei More than 80% o